Beta cell function: difference between revisions
Diff·revision 16 → 17·03:54, 4 Jun 2025
Difference between revision 16 and revision 17 of Beta cell function. 5 lines changed; the page grew by 813 bytes.
| Revision 16 — 02:01, 8 May 2025 Chromatokid (talk) add the cleavage site by residue number 4,938 bytes +22 | Revision 17 — 03:54, 4 Jun 2025 GsCouplingGil (talk) fix a broken wikilink 5,751 bytes +813 | ||
|---|---|---|---|
| 34 | Reference intervals for all of these are population- and assay-specific. A HOMA-B value quoted without the insulin assay it was derived from is not interpretable, because insulin immunoassays differ in cross-reactivity with proinsulin.{{r|rorsman2013,matthews1985}} | 34 | Reference intervals for all of these are population- and assay-specific. A HOMA-B value quoted without the insulin assay it was derived from is not interpretable, because insulin immunoassays differ in cross-reactivity with proinsulin.{{r|rorsman2013,matthews1985}} |
| 35 | 35 | ||
| + | 36 | == Change under treatment and weight loss == | |
| + | 37 | Incretin therapy improves several indices of beta-cell function while treatment continues. Whether this constitutes a durable change in the beta cell or simply reflects amplification of secretion while the drug is present has been debated since the first trials, and the honest answer is that most published improvements have not persisted through a washout period.{{r|drucker2018}} | |
| + | 38 | ||
| + | 39 | Substantial weight loss by any means improves the disposition index, and remission studies following large sustained weight loss have reported recovery of first-phase secretion in a subset of participants — most often those with shorter diabetes duration. This is the strongest available evidence that some of the functional loss in type 2 diabetes is reversible.{{r|bergman2002}} | |
| + | 40 | ||
| 36 | == References == | 41 | == References == |
| 37 | {{reflist}} | 42 | {{reflist}} |